Recent News

• 04.15.2025 - 2025 Cell & Gene Meeting
• 04.15.2025 - 2025 Cell & Gene Meeting
• 04.08.2025 - Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
• 04.08.2025 - Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
• 04.08.2025 - Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
• 03.18.2025 - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
• 03.18.2025 - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
• 03.18.2025 - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
• 03.05.2025 - Ocugen, Inc. Q4 and Full Year 2024 Financial Results and Business Highlights
• 03.05.2025 - Ocugen, Inc. Q4 and Full Year 2024 Financial Results and Business Highlights

Recent Filings

• 04.04.2025 - EX-99.1 EX-99.1
• 04.04.2025 - 8-K Current report
• 03.05.2025 - EX-99.1 EX-99.1
• 03.05.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.05.2025 - 8-K Current report
• 03.05.2025 - S-8 Securities to be offered to employees in employee benefit plans